Novolog Mix 50/50 is a drug owned by Novo Nordisk Inc. It is protected by 7 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 20, 2017. Details of Novolog Mix 50/50's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5866538 (Pediatric) | Insulin preparations containing NaCl |
Dec, 2017
(6 years ago) |
Expired
|
| US5866538 | Insulin preparations containing NaCl |
Jun, 2017
(7 years ago) |
Expired
|
|
US5618913 (Pediatric) | Insulin analogues |
Dec, 2014
(9 years ago) |
Expired
|
| US5618913 | Insulin analogues |
Jun, 2014
(10 years ago) |
Expired
|
| US5834422 | AspB28 insulin compositions |
Sep, 2013
(11 years ago) |
Expired
|
| US5547930 | AspB28 insulin crystals |
Sep, 2013
(11 years ago) |
Expired
|
| US5840680 | ASPB28 insulin crystals |
Sep, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Novolog Mix 50/50 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Novolog Mix 50/50's family patents as well as insights into ongoing legal events on those patents.
Novolog Mix 50/50's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Novolog Mix 50/50's generic launch date based on the expiry of its last outstanding patent is estimated to be Dec 20, 2017 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Novolog Mix 50/50 Generics:
There are no approved generic versions for Novolog Mix 50/50 as of now.
Alternative Brands for Novolog Mix 50/50
Novolog Mix 50/50 which is used for managing diabetes mellitus., has several other brand drugs in the same treatment category and using the same active ingredient (Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||
|---|---|---|---|---|---|---|---|---|
| Novo Nordisk Inc |
| |||||||
| Sanofi Aventis Us |
| |||||||
About Novolog Mix 50/50
Novolog Mix 50/50 is a drug owned by Novo Nordisk Inc. It is used for managing diabetes mellitus. Novolog Mix 50/50 uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as an active ingredient. Novolog Mix 50/50 was launched by Novo Nordisk Inc in 2008.
Approval Date:
Novolog Mix 50/50 was approved by FDA for market use on 26 August, 2008.
Active Ingredient:
Novolog Mix 50/50 uses Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant as the active ingredient. Check out other Drugs and Companies using Insulin Aspart Protamine Recombinant; Insulin Aspart Recombinant ingredient
Treatment:
Novolog Mix 50/50 is used for managing diabetes mellitus.
Dosage:
Novolog Mix 50/50 is available in injectable form for subcutaneous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 50 UNITS/ML;50 UNITS/ML | INJECTABLE | Discontinued | SUBCUTANEOUS |